Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma

Leukemia and Lymphoma

Volumn 54, Issue 7, 2013, Pages 1473-1478

  Bhaskar, Archana ^a,c   Gupta, Ritu ^a   Vishnubhatla, Sreenivas ^b   Kumar, Lalit ^a   Sharma, Atul ^a   Sharma, Mehar Chand ^b   Das, Prasenjit ^b   Thakur, Sonu Chand ^c  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

Author keywords

Angiogenesis; Angiopoietin; Endothelial progenitor cells; Hypoxia inducible factor 1 ; Multiple myeloma

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; FIBROBLAST GROWTH FACTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; BONE MARROW; CAPILLARY DENSITY; CONTROLLED STUDY; DISEASE ACTIVITY; ENDOTHELIAL PROGENITOR CELL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; ANGIOGENIC PROTEINS; ANGIOPOIETINS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84879396076     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.745523     Document Type: Article

References (31)

1. C armeliet P, J ain R K. A ngiogenesis in cancer and other diseases. Nature 2000;407:249-257.
2. Sato Y. Molecular diagnosis of tumor angiogenesis and antiangiogenic cancer therapy. Int J Clin Oncol 2003; 8: 200-206. (Pubitemid 37122254)
3. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24:22-32.
4. Yata K, Otsuki T, Kurebayashi J, et al. Expression of angiogenic factors including VEGFs and the eff ects of hypoxia and thalidomide on human myeloma cells. Int J Oncol 2003;22:165-173.
5. Vacca A, Scavelli C, Montefusco V, et al. Thalidomide down regulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 2005;23 : 5334-5346. (Pubitemid 46206987)
6. Dmoszyńska A, Bojarska-Junak A, D oman ́ ski D, et al. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymphoma 2002; 43: 401-406. (Pubitemid 34202122)
7. N eben K, M oehler T, E gerer G, et al. H igh plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res 2001;7:2675-2681. (Pubitemid 32911371)
8. Terpos E, Anargyrou K, Katodritou E, et al. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. Int J Cancer 2012;130:735-742.
9. Zhang J, Sattler M, Tonon G, et al. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res 2009; 69: 5082-5090.
10. Zhang H, Vakil V, Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005;105:3286-3294.
11. Bhaskar A, Gupta R, Kumar L et al. Circulating endothelial progenitor cells as potential prognostic biomarker in multiple myeloma. Leuk Lymphoma 2012; 53: 635-640.
12. Koh GY, Kim I, Kwak HJ, et al. Biomedical significance of endothelial cell specific growth factor, angiopoietin. Exp Mol Med 2002;34:1-11. (Pubitemid 34408199)
13. Chavakis E, Dimmeler S. Regulation of endothelial cell survival and apoptosis during angiogenesis. Arterioscler Th romb Vasc Biol 2002;22:887-893. (Pubitemid 34655213)
14. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676. (Pubitemid 36749215)
15. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 2: 116-129.
16. Huang H, Bhat A, Woodnutt G, et al. Targeting the ANGPT-TIe2 pathway in malignancy. Nat Rev Cancer 2010; 10: 575-585.
17. Holash J, Maisonpierre P C, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-1998. (Pubitemid 29309448)
18. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders:a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
19. Bhatti SS, Kumar L, Dinda AK, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological and laboratory parameters. Am J Hematol 2006;81:649-656. (Pubitemid 44306822)
20. Durie BGM, Harousseau J-L, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473. (Pubitemid 44264086)
21. Pour L, Svachova H, Adam Z et al. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol 2010;89:385-389.
22. Colla S, Tagliaferri S, Morandi F et al. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity:involvement in myeloma-induced angiogenesis. Blood 2007;110:4464-4475. (Pubitemid 351377813)
23. H ata K, N akayama K, F ujiwaki R, et al. E xpression of the angiopoietin-1, angiopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. Gynecol Oncol 2004; 93: 215-222. (Pubitemid 38429573)
24. Ochiumi T, Tanaka S, Oka S, et al. Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma. Int J Oncol 2004; 24: 539-547.
25. Pouyss é gur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441 : 437-443. (Pubitemid 44050138)
26. Takenaga K. Angiogenic signaling aberrantly induced by tumor hypoxia. Front Biosci 2011;16:31-48.
27. Veschini L, Belloni D, Foglieni C, et al. Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. Blood 2007;109:2565-2570. (Pubitemid 46425903)
28. Ribbatti D. Tyrosine kinase inhibitors as antiangiogenic drugs in multiple myeloma. Pharmaceuticals 2010; 3: 1225-1231.
29. Laubach JP, Mahindra A, Mitsiades CS, et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009; 23: 2222-2232.
30. Palumbo A, Magarotto V. Novel treatment paradigm for elderly patients with multiple myeloma. Am J Blood Res 2011;1:190-204.
31. Prince HM, H ö nemann D, Spencer A, et al. Vascular endothelial growth factor inhibition is not an eff ective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). Blood 2009;113:4819-4820.